Protocol No
DF-HCC-17-273AML-ASCT
Principal Investigator
Sameem Abedin
Phase
II
Summary
Trying to discover if Ruxolitinib will decrease your chances of relapse after having an allogeneic stem cell transplantation.
Description
Ruxolitinib after Allogeneic Stem Cell Transplantation in AML
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov